[ CAS No. 82771-60-6 ] {[proInfo.proName]}

Name: 82771-60-6|7-Chloro-1,2,3,4-tetrahydroisoquinoline|97%
Brand: Ambeed
SKU: A433173
Price: 53.0 USD
Availability: InStock
Rating: 90 (27 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 82771-60-6

Structure of 82771-60-6 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 82771-60-6 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 82771-60-6 ]

SDS Specification

Alternatived Products of [ 82771-60-6 ]

Product Details of [ 82771-60-6 ]

CAS No. :	82771-60-6	MDL No. :	MFCD05861543
Formula :	C₉H₁₀ClN	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	BLRKQLICTKRDDZ-UHFFFAOYSA-N
M.W :	167.64	Pubchem ID :	12595069
Synonyms :

Calculated chemistry of [ 82771-60-6 ]

Physicochemical Properties

Num. heavy atoms :	11
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.33
Num. rotatable bonds :	0
Num. H-bond acceptors :	1.0
Num. H-bond donors :	1.0
Molar Refractivity :	50.79
TPSA :	12.03 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-5.94 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.18
Log Po/w (XLOGP3) :	1.95
Log Po/w (WLOGP) :	1.45
Log Po/w (MLOGP) :	2.37
Log Po/w (SILICOS-IT) :	3.08
Consensus Log Po/w :	2.21

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	2.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-2.51
Solubility :	0.516 mg/ml ; 0.00308 mol/l
Class :	Soluble
Log S (Ali) :	-1.83
Solubility :	2.49 mg/ml ; 0.0149 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-3.89
Solubility :	0.0217 mg/ml ; 0.00013 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.49

Safety of [ 82771-60-6 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P280-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H332-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 82771-60-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 82771-60-6 ]
Downstream synthetic route of [ 82771-60-6 ]

[ 82771-60-6 ] Synthesis Path-Upstream 1~16

1
[ 82771-60-6 ]
[ 60518-41-4 ]

Yield	Reaction Conditions	Operation in experiment
915 mg	With manganese(IV) oxide In dichloromethane at 20℃; for 16 h;	Example 32: 7-Chloro-3,4-dihydroisoquinoline Int-50 [00379] To a solution of 7-chloro-l ,2,3,4-tetrahydro-isoquinoline ( 1.15 g, 6.86 mmol) in DCM (70.0 mL, 1090 mmol) was added Mn0₂ (5.96 g, 68.6 mmol) at rt, and the mixture was stirred for 16h. The reaction was filtered through a Celite pad and the residual solid was rinsed with DCM several times. The filtrate was concentrated in vacuo and the residue was purified by ISCO silica gel column chromatography (40g, eluting with 50percent EtOAc in DCM, 50mL/min flow) to give 915 mg of the title compound as colorless solid. NMR (400 MHz, DMSO-d6) δ 8.35 (t, J = 2.1 Hz, 1H), 7.52 (d, J = 2.2 Hz, 1H), 7.46 (dd, J = 8.0, 2.3 Hz, 1H), 7.28 (d, J = 8.0 Hz, 1H), 3.70 - 3.63 (m, 2H), 2.71 - 2.65 (m, 2H).

Reference： [1] Patent: WO2016/4136, 2016, A1, . Location in patent: Paragraph 00379

2
[ 34784-06-0 ]
[ 82771-60-6 ]

Reference： [1] Journal of Medicinal Chemistry, 1980, vol. 23, # 5, p. 506 - 511

3
[ 1004522-39-7 ]
[ 82771-60-6 ]

Reference： [1] Journal of Organic Chemistry, 2008, vol. 73, # 1, p. 312 - 315
[2] Organic Syntheses, 2013, vol. 90, p. 251 - 260

4
[ 64834-58-8 ]
[ 82771-60-6 ]
[ 75416-50-1 ]

Reference： [1] Tetrahedron, 2018, vol. 74, # 49, p. 7009 - 7017

5
[ 111875-09-3 ]
[ 82771-60-6 ]

Reference： [1] Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1986, p. 1977 - 1982

6
[ 156-41-2 ]
[ 82771-60-6 ]

Reference： [1] Bioorganic and Medicinal Chemistry, 2002, vol. 10, # 1, p. 87 - 95
[2] Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1986, p. 1977 - 1982

7
[ 140-53-4 ]
[ 82771-60-6 ]

8
[ 78104-41-3 ]
[ 82771-60-6 ]

Reference： [1] Bioorganic and Medicinal Chemistry, 2002, vol. 10, # 1, p. 87 - 95

9
[ 88422-94-0 ]
[ 82771-60-6 ]

Reference： [1] Bioorganic and Medicinal Chemistry, 2002, vol. 10, # 1, p. 87 - 95

10
[ 111874-99-8 ]
[ 82771-60-6 ]

Reference： [1] Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1986, p. 1977 - 1982

11
[ 89-98-5 ]
[ 82771-60-6 ]
[ 75416-50-1 ]

Reference： [1] Tetrahedron, 2018, vol. 74, # 49, p. 7009 - 7017

12
[ 71006-02-5 ]
[ 82771-60-6 ]
[ 75416-50-1 ]

Reference： [1] Tetrahedron, 2018, vol. 74, # 49, p. 7009 - 7017

13
[ 64834-58-8 ]
[ 82771-60-6 ]
[ 75416-50-1 ]

Reference： [1] Tetrahedron, 2018, vol. 74, # 49, p. 7009 - 7017

14
[ 89-98-5 ]
[ 82771-60-6 ]
[ 75416-50-1 ]

Reference： [1] Tetrahedron, 2018, vol. 74, # 49, p. 7009 - 7017

15
[ 71006-02-5 ]
[ 82771-60-6 ]
[ 75416-50-1 ]

Reference： [1] Tetrahedron, 2018, vol. 74, # 49, p. 7009 - 7017

16
[ 82771-60-6 ]
[ 73075-45-3 ]

Reference： [1] Tetrahedron, 2018, vol. 74, # 49, p. 7009 - 7017

[ 82771-60-6 ] Synthesis Path-Downstream 1~76

1
[ 34784-06-0 ]
[ 82771-60-6 ]

Reference： [1]Journal of Medicinal Chemistry,1980,vol. 23,p. 506 - 511

2
[ 82771-60-6 ]
C₁₈H₁₉Cl₂N₃O₄S₂ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1982,vol. 25,p. 1235 - 1240

3
[ 82771-60-6 ]
[ 88-89-1 ]
[ 125407-00-3 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1986,p. 1977 - 1982

4
[ 111875-09-3 ]
[ 82771-60-6 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1986,p. 1977 - 1982

6
[ 82771-60-6 ]
[ 5394-18-3 ]
[ 732239-09-7 ]

Reference： [1]Medicinal Chemistry Research,2001,vol. 10,p. 634 - 643
[2]Bioorganic and Medicinal Chemistry,2002,vol. 10,p. 87 - 95

7
[ 78104-41-3 ]
[ 82771-60-6 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2002,vol. 10,p. 87 - 95

8
[ 1120-87-2 ]
[ 82771-60-6 ]
7-Chloro-2-pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2003,vol. 13,p. 1759 - 1762

9
[ 82771-60-6 ]
8-{4-[2-(7-chloro-1,2,3,4-tetrahydroisoquinolinyl)]butyl}-8-azaspiro[5,4]decane-7,9-dione [ No CAS ]

Reference： [1]Medicinal Chemistry Research,2001,vol. 10,p. 634 - 643

10
[ 82771-60-6 ]
[ 392660-75-2 ]

Reference： [1]Medicinal Chemistry Research,2001,vol. 10,p. 634 - 643
[2]Bioorganic and Medicinal Chemistry,2002,vol. 10,p. 87 - 95

11
[ 82771-60-6 ]
adamantane-1-carboxylic acid [4-(7-chloro-3,4-dihydro-1<i>H</i>-isoquinolin-2-yl)-butyl]-amide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2002,vol. 10,p. 87 - 95

12
[ 88422-94-0 ]
[ 82771-60-6 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2002,vol. 10,p. 87 - 95

13
[ 156-41-2 ]
[ 82771-60-6 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2002,vol. 10,p. 87 - 95
[2]Journal of the Chemical Society. Perkin transactions I,1986,p. 1977 - 1982
[3]Organic Letters,2019,vol. 21,p. 1438 - 1443
[4]European Journal of Organic Chemistry,2019,vol. 2019,p. 3649 - 3653
[5]Chemical Communications,2019,vol. 55,p. 12072 - 12075

14
[ 140-53-4 ]
[ 82771-60-6 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2002,vol. 10,p. 87 - 95
[2]Journal of the Chemical Society. Perkin transactions I,1986,p. 1977 - 1982

15
[ 111874-99-8 ]
[ 82771-60-6 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1986,p. 1977 - 1982

16
3-[2-(4-Chloro-phenyl)-ethyl]-hydroxymethyl-sulfamoyl}-propionic acid methyl ester [ No CAS ]
[ 82771-60-6 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1986,p. 1977 - 1982

17
[ 1004522-39-7 ]
[ 82771-60-6 ]

Reference： [1]Journal of Organic Chemistry,2008,vol. 73,p. 312 - 315
[2]Organic Syntheses,2013,vol. 90,p. 251 - 260

18
[ 82771-60-6 ]
[ 1028331-11-4 ]
[ 1028330-59-7 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2008,vol. 18,p. 2544 - 2548

19
[ 82771-60-6 ]
[ 1066821-85-9 ]
C₂₄H₂₀Cl₂N₂O₅S [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2008,vol. 18,p. 5018 - 5022

20
[ 591-50-4 ]
[ 82771-60-6 ]
7-chloro-2-phenyl-1,2,3,4-tetrahydroisoquinoline [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With potassium phosphate; copper(l) iodide; ethylene glycol; In isopropyl alcohol; at 20℃;Inert atmosphere;	General procedure: A mixture of CuI (10 mmol%) and K3PO4 (3.0 equiv.) was taken in a two necked round bottom flask evacuated and backfilled with nitrogen and fitted on oil bath. 2-Propanol (10 mL), ethylene glycol (1.1 mL), 1,2,3,4-tetrahydroisoqunoline (15 mmol, 2.0mL) and aryl iodide (10 mmol, 1.12 mL) were added successively by microsyring at rt. The reaction mixture was heated at 80-90 oC with stirring for 24-36 h. After the completion of the reaction was allowed to cool at rt. Diethyl ether (20 mL) and water (20 mL) was added to reaction mixture. The organic layer was extracted by diethyl ether (2 × 20mL). The combined organic layer was washed with brine and dried over magnesium sulfate. The solvent was removed by rotary evaporator and the crude product was purified by column chromatography on silica gel with a mixture of hexane/ethyl acetate as eluent to afford an analytically pure sample of substrates 1.

Reference： [1]Journal of the American Chemical Society,2010,vol. 132,p. 1464 - 1465
[2]Tetrahedron Letters,2015,vol. 56,p. 6696 - 6699

21
[ 82771-60-6 ]
[ 1416177-69-9 ]
[ 1422437-03-3 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 351 - 354

22
[ 82771-60-6 ]
[ 445-27-2 ]
10-chloro-11b,12-dihydro-6H-isoquinolino[2,1-a]quinolin-13(7H)-one [ No CAS ]

Reference： [1]Advanced Synthesis and Catalysis,2013,vol. 355,p. 874 - 879

23
[ 82771-60-6 ]
[ 445-27-2 ]
1-(2-(7-chloro-3,4-dihydroisoquinolin-2(1H)-yl)phenyl)ethanone [ No CAS ]

Reference： [1]Advanced Synthesis and Catalysis,2013,vol. 355,p. 874 - 879

24
[ 82771-60-6 ]
[ 41882-26-2 ]
3-chloro-5-ethyl-12,13-dihydro-4bH-isoquinolino[2,1-a]quinazolin-6(5H)-one [ No CAS ]

Reference： [1]RSC Advances,2014,vol. 4,p. 2694 - 2704

25
[ 82771-60-6 ]
[ 41882-26-2 ]
C₁₈H₁₉ClN₂O [ No CAS ]

Reference： [1]RSC Advances,2014,vol. 4,p. 2694 - 2704

26
C₉H₁₁Cl₂N [ No CAS ]
[ 82771-60-6 ]

Reference： [1]Organic Syntheses,2013,vol. 90,p. 251 - 260

27
[ 82771-60-6 ]
[ 215790-29-7 ]
tert-butyl (trans-4-(2-(7-chloro-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)carbamate [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2015,vol. 58,p. 5287 - 5307
[2]Journal of Medicinal Chemistry,2019,vol. 62,p. 4755 - 4771

28
[ 82771-60-6 ]
N-(trans-4-(2-(7-chloro-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2015,vol. 58,p. 5287 - 5307

29
[ 82771-60-6 ]
trans-4-(2-(7-chloro-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexanamine [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2015,vol. 58,p. 5287 - 5307

30
[ 591-50-4 ]
[ 82771-60-6 ]
C₁₆H₁₃ClN₂S [ No CAS ]

Reference： [1]Tetrahedron Letters,2015,vol. 56,p. 6696 - 6699

31
[ 82771-60-6 ]
(1S)-7-chloro-1-[5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl]-1,2,3,4-tetrahydroisoquinoline [ No CAS ]

Reference： [1]Patent: WO2016/4136,2016,A1

32
[ 82771-60-6 ]
(1R)-7-chloro-1-[5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl]-1,2,3,4-tetrahydroisoquinoline [ No CAS ]

Reference： [1]Patent: WO2016/4136,2016,A1

33
[ 82771-60-6 ]
tert-butyl (1R)-7-chloro-1-(5-formyl-2-methyl-3-thienyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate [ No CAS ]

Reference： [1]Patent: WO2016/4136,2016,A1

34
[ 82771-60-6 ]
tert-butyl (R)-1-(5-(1,3-dioxolan-2-yl)-2-methylthiophen-3-yl)-7-chloro-3,4-dihydroisoquinoline-2(1H)-carboxylate [ No CAS ]

Reference： [1]Patent: WO2016/4136,2016,A1

35
[ 82771-60-6 ]
C₂₄H₂₃Cl₂N₃O₃S [ No CAS ]

Reference： [1]Patent: WO2016/4136,2016,A1

36
[ 82771-60-6 ]
tert-butyl (1R)-7-chloro-1-[5-[4-[[(1R,3S,4R)-3-hydroxy-4-(suIfamoyloxymethyl)cyclopentyl]amino]pyrimidine-5-carbonyl]-2-methyl-3-thienyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate [ No CAS ]

Reference： [1]Patent: WO2016/4136,2016,A1
[2]Patent: WO2016/4136,2016,A1

37
[ 82771-60-6 ]
[(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-thiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxy-cyclopentyl]methyl sulfamate [ No CAS ]

Reference： [1]Patent: WO2016/4136,2016,A1
[2]Patent: WO2016/4136,2016,A1
[3]Patent: WO2016/4136,2016,A1
[4]Patent: WO2016/4136,2016,A1

38
[ 82771-60-6 ]
((1R,2S,4R)-4-((5-(4-(7-chloro-3,4-dihydroisoquinolin-1-yl)-5-methylthiophene-2-carbonyl)pyrimidin-4-yl)amino)-2-hydroxycyclopentyl)methyl sulfamate [ No CAS ]

Reference： [1]Patent: WO2016/4136,2016,A1
[2]Patent: WO2016/4136,2016,A1
[3]Patent: WO2016/4136,2016,A1
[4]Patent: WO2016/4136,2016,A1

39
[ 82771-60-6 ]
[ 60518-41-4 ]

Yield	Reaction Conditions	Operation in experiment
915 mg	With manganese(IV) oxide; In dichloromethane; at 20℃; for 16h;	Example 32: 7-Chloro-3,4-dihydroisoquinoline Int-50 [00379] To a solution of 7-chloro-l ,2,3,4-tetrahydro-isoquinoline ( 1.15 g, 6.86 mmol) in DCM (70.0 mL, 1090 mmol) was added Mn02 (5.96 g, 68.6 mmol) at rt, and the mixture was stirred for 16h. The reaction was filtered through a Celite pad and the residual solid was rinsed with DCM several times. The filtrate was concentrated in vacuo and the residue was purified by ISCO silica gel column chromatography (40g, eluting with 50% EtOAc in DCM, 50mL/min flow) to give 915 mg of the title compound as colorless solid. NMR (400 MHz, DMSO-d6) delta 8.35 (t, J = 2.1 Hz, 1H), 7.52 (d, J = 2.2 Hz, 1H), 7.46 (dd, J = 8.0, 2.3 Hz, 1H), 7.28 (d, J = 8.0 Hz, 1H), 3.70 - 3.63 (m, 2H), 2.71 - 2.65 (m, 2H).

Reference： [1]Patent: WO2016/4136,2016,A1 .Location in patent: Paragraph 00379

40
[ 82771-60-6 ]
tert-butyl 7-chloro-1-(5-formyl-2-methyl-3-thienyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate [ No CAS ]

Reference： [1]Patent: WO2016/4136,2016,A1

41
[ 82771-60-6 ]
tert-butyl 7-chloro-1-[5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl]-3,4-dihydroisoquinoline-2(1H)-carboxylate [ No CAS ]

Reference： [1]Patent: WO2016/4136,2016,A1

42
[ 82771-60-6 ]
7-chloro-1-[5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl]-1,2,3,4-tetrahydroisoquinoline [ No CAS ]

Reference： [1]Patent: WO2016/4136,2016,A1

43
[ 82771-60-6 ]
tert-butyl 7-chloro-1-{5-[(4-chloropyrimidin-5-yl)(hydroxy)methyl]-2-methyl-3-thienyl}-3,4-dihydroisoquinoline-2(1H)-carboxylate [ No CAS ]

Reference： [1]Patent: WO2016/4136,2016,A1

44
[ 82771-60-6 ]
C₂₄H₂₃Cl₂N₃O₃S [ No CAS ]

Reference： [1]Patent: WO2016/4136,2016,A1

45
[ 82771-60-6 ]
tert-butyl (1R)-7-chloro-1-[5-[4-[[(1R,3R,4S)-3-(hydroxymethyl)-4-triisopropylsilyloxy-cyclopentyl]amino]pyrimidine-5-carbonyl]-2-methyl-3-thienyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate [ No CAS ]

Reference： [1]Patent: WO2016/4136,2016,A1

46
[ 82771-60-6 ]
tert-butyl (1R)-7-chloro-1-[5-[4-[[(1R,3R,4S)-3-(hydroxymethyl)-4-triisopropylsilyloxy-cyclopentyl]amino]pyrimidine-5-carbonyl]-2-methyl-3-thienyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate [ No CAS ]
tert-butyl (1S)-7-chloro-1-[5-[4-[[(1R,3R,4S)-3-(hydroxymethyl)-4-triisopropylsilyloxy-cyclopentyl]amino]pyrimidine-5-carbonyl]-2-methyl-3-thienyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate [ No CAS ]

Reference： [1]Patent: WO2016/4136,2016,A1

47
[ 82771-60-6 ]
tert-butyl (1R)-7-chloro-1-[2-methyl-5-[4-[[(1R,3R,4S)-3-(sulfamoyloxymethyl)-4-triisopropylsilyloxy-cyclopentyl]amino]pyrimidine-5-carbonyl]-3-thienyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate [ No CAS ]

Reference： [1]Patent: WO2016/4136,2016,A1
[2]Patent: WO2016/4136,2016,A1

48
[ 82771-60-6 ]
[ 24424-99-5 ]
tert-butyl 7-chloro-3,4-dihydroisoquinoline-2(1H)-carboxylate [ No CAS ]

Reference： [1]Organic and Biomolecular Chemistry,2016,vol. 14,p. 4908 - 4917

49
[ 82771-60-6 ]
tert-butyl 1-allyl-7-chloro-3,4-dihydroisoquinoline-2(1H)-carboxylate [ No CAS ]

Reference： [1]Organic and Biomolecular Chemistry,2016,vol. 14,p. 4908 - 4917

50
[ 82771-60-6 ]
tert-butyl 7-chloro-3,4-dihydro-1-(trimethylsilyl)isoquinoline-2(1H)-carboxylate [ No CAS ]

Reference： [1]Organic and Biomolecular Chemistry,2016,vol. 14,p. 4908 - 4917

51
[ 82771-60-6 ]
tert-butyl 1-(tributylstannyl)-7-chloro-3,4-dihydroisoquinoline-2(1H)-carboxylate [ No CAS ]

Reference： [1]Organic and Biomolecular Chemistry,2016,vol. 14,p. 4908 - 4917

52
[ 82771-60-6 ]
[ 1453083-78-7 ]
5-(2-(7-chloro-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-3,3-diethyl-dihydrofuran-2(3H)-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With potassium carbonate; In acetonitrile; for 72h;Reflux;	To a solution of 3,3-diethyl-5-(2-(4-(4-hydroxyphenyl)piperazin- 1-yl)ethyl)dihydrofuran-2(3H)-one (50 mg, 0.147 mmol, 1 eq.) in acetonitrile (1.5 mL) was added K2C03 (91 mg, 0.658 mmol, 4.5 eq.). Then, <strong>[82771-60-6]7-chloro-1,2,3,4-tetrahydroisoquinoline</strong> (37 mg, 0.220 mmol, 1.5 eq.) was added and the reaction mixture was allowed to stir at reflux for 3 days. The mixture was filtered through a glass pipet packed with glass wool and washed with acetonitrile. The filtrate was concentrated under reduced pressure to afford a crude oil which was purified through flash chromatography (silica; methanol/dichloromethane, 0% 10%) to provide 5-(2-(7-chloro-3,4-dihydroisoquinolin-2( 1 H)-yl)ethyl)-3,3 -diethyldihydrofuran2(3H)-one 5 -(2-(7-chloro-3 ,4-dihydroisoquinolin-2(1 H)-yl)ethyl)-3 ,3 -diethyl-dihydrofuran2(3H)-one: 1 ?H NMR (400 MHz, CDC13) oe 7.02 (dd, J = 2.2, 8.2, 1H), 6.95 (m, 2H), 4.45 (m, 1H), 3.52 (s, 2H), 2.77 (m, 2H), 2.63 (m, 4H), 2.07 (dd, J = 6.7, 13.0, 1H), 1.83 (m, 3H), 1.55 (qd, J= 1.2, 7.3, 4H), 0.85 (dt, J= 7.5, 15.3, 6H) LC/MS [M+Hj= m/z 336.1.

Reference： [1]Patent: WO2016/183150,2016,A1 .Location in patent: Paragraph 0560; 0561

53
[ 82771-60-6 ]
[ 1896-62-4 ]
(4R,11bS)-10-chloro-4-phenyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one [ No CAS ]
(4S,11bR)-10-chloro-4-phenyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one [ No CAS ]
10-chloro-4-phenyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one [ No CAS ]

Reference： [1]Advanced Synthesis and Catalysis,2017,vol. 359,p. 3095 - 3101

54
[ 62595-74-8 ]
[ 82771-60-6 ]
3-(7-chloro-3,4-dihydroisoquinolin-2(1H)-yl)piperidine-2,6-dione [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
62%	With N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; for 16h;	7- Chloro-1,2,3,4-tetrahydroisoquinoline (75.0 mg) was dissolved in DMF (0.7 mL). MA6-019 (86.0 mg) and DIPEA (a56.8 muL) were added into the mixture and stirred for 16 h. Purification by washing with aq. NaHCO3 (5 mL) and trituration from ethyl acetate/hexanes gave MA7-074 as a biege solid (77 mg, 62%). HPLC: >99% [tR = 11.6 min, 15% MeOH, 85 water (with 0.1% TFA), 20 min]. 1H NMR (400 MHz, DMSO) delta 10.71 (s, 1H), 7.17-7.11 (m , 3H), 3.94 (d, J = 16 Hz, 1H), 3.79 (d, J = 16 Hz, 1H), 3.65 (dd J = 8.0, J = 4.0, 1H), 2.90-2.95 (m, 1H), 2.90-2.81 (m, 1H), 2.70-2.80 (m, 2H), 2.65-2.50 (m, 2H), 2.20-2.08 (m, 1H), 1.95-1.85 (m, 1H). HRMS (ESI+): m/z calcd for C14H16ClN2O2 (M+H)+ 279.0894, found 279.0894, m/z calcd for C14H15ClN2O2Na (M+Na)+ 301.0714, found 301.0711. HPLC-MS: HPLC-MS (ESI+): m/z 279.2 [40%, (M+H)+], 277.1 [100%, (M-H)-].

Reference： [1]Patent: WO2017/161119,2017,A1 .Location in patent: Page/Page column 119

55
[ 82771-60-6 ]
[ 69360-26-5 ]
2-((7-chloro-3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)benzonitrile [ No CAS ]

Reference： [1]Chemistry - A European Journal,2018,vol. 24,p. 3434 - 3438

56
[ 82771-60-6 ]
[ 69360-26-5 ]
(E)-ethyl 3-(7-chloro-2-((2-cyanophenyl)sulfonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)acrylate [ No CAS ]
(E)-ethyl 3-(7-chloro-2-((2-cyanophenyl)sulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)acrylate [ No CAS ]

Reference： [1]Chemistry - A European Journal,2018,vol. 24,p. 3434 - 3438

57
[ 82771-60-6 ]
[ 20782-91-6 ]
7-chloro-2-((5-nitrofuran-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
81%	With potassium carbonate; In N,N-dimethyl-formamide; at 20℃;	General procedure: To a solution of compound 5 (1.0eq.) and Ia-f (1.0eq.) was added K2CO3 (2.2eq.) in anhydrous DMF at RT. After stirring for 5-7h, the reaction was diluted with water and the precipitation was filtered to afford the crude targets. Then the crude target was purified by flash column chromatography (EtOAc : PE=1 : 5) to afford the compounds 6a-f. Targets 7a-e, 8a-d and 9a-c were obtained as the procedure for 6a-f by the reaction of compound 5 witha-e, IIIa-d and IVa-c.

Reference： [1]Bioorganic and Medicinal Chemistry,2018,vol. 26,p. 2073 - 2084

58
[ 82771-60-6 ]
[ 400859-08-7 ]
7-chloro-2-(2-pyrimidin-2-ylpyrimidin-5-yl)-3,4-dihydro-l /-isoquinoline [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
26 mg	With [(2-di-cyclohexylphosphino-3,6-dimethoxy-2?,4?,6?-triisopropyl-1,1?-biphenyl)-2-(2?-amino-1,1?-biphenyl)]palladium(II) methanesulfonate; caesium carbonate; In 1,4-dioxane; at 120℃; for 48h;Inert atmosphere;	To a mixture of 7-chloro- l,2,3,4-tetrahydroisoquinoline (200 mg, 1.19 mmol), 5-bromo-2- pyrimidin-2-yl-pyrimidine (226 mg, 954 muiotaetaomicron, the product of step 3 in Example 1) and CS2CO3 (1.94 g, 5.97 mmol) in dioxane (15 mL) was added Brettphos Pd G3 (216 mg, 239 muiotaetaomicron, CAS registry number: 1470372-59-8). The resulting mixture was heated at 120 C with stirring for 48 hrs under N2 and filtered. The filtrate was concentrated in vacuo. The residue was purified by prep-HPLC to give 7-chloro-2-(2-pyrimidin-2-ylpyrimidin-5-yl)-3,4-dihydro- lH-isoquinoline (0436) (26 mg) as light yellow solid. XH NMR (400 MHz, Methanol-^) delta ppm: 8.87-8.99 (m, 2H), 8.55- 8.70 (m, 2H), 7.45-7.59 (m, IH), 7.25-7.38 (m, IH), 7.21 (s, 2H), 4.62 (s, 2H), 3.76 (t, 2H), 3.02 (s, 2H). MS obsd. (ESI+) [(M+H)+] : 324

Reference： [1]Patent: WO2018/83136,2018,A1 .Location in patent: Page/Page column 51

59
[ 64834-58-8 ]
[ 82771-60-6 ]
[ 75416-50-1 ]

Yield	Reaction Conditions	Operation in experiment
	With aluminum (III) chloride; ammonium chloride; at 185℃; for 23h;	To the mixture of 20 (10.00?g, 45.05?mmol) and ammonium chloride (1.76?g, 32.9?mmol), aluminum chloride (11.60?g, 87.02?mmol) was added at 185?C. After 40?min and 70?min, further portions of aluminum chloride (5.80?g, 43.5?mmol and 11.60?g, 87.02?mmol) were added and the mixture was stirred for further 23?h?at the same temperature. It was poured into a slurry of ice and 3?M HCl solution under strong agitation. The resulting solution was basified (pH 14) with 40% NaOH and extracted with diethyl ether (300?mL and 2?*?150?mL). The organic layer was dried (MgSO4), and evaporated resulting in an oily residue (7.07?g, 94%) containing the two isomers 19 and 27 in a ratio of 9: 1 as determined by GC-MS. It was dissolved in isopropyl alcohol (50?mL) and a solution of hydrochloric acid gas in isopropyl alcohol was added dropwise. The precipitate was filtered off. The residue was recrystallized twice from isopropyl alcohol to afford the title compound (2.32?g, 25%)

Reference： [1]Tetrahedron,2018,vol. 74,p. 7009 - 7017

60
[ 89-98-5 ]
[ 82771-60-6 ]
[ 75416-50-1 ]

Reference： [1]Tetrahedron,2018,vol. 74,p. 7009 - 7017

61
[ 71006-02-5 ]
[ 82771-60-6 ]
[ 75416-50-1 ]

Reference： [1]Tetrahedron,2018,vol. 74,p. 7009 - 7017

62
[ 82771-60-6 ]
[ 73075-45-3 ]

Yield	Reaction Conditions	Operation in experiment
	With hydrogenchloride; In Isopropyl acetate; toluene;	The corresponding hydrochloride salt was prepared by addition of a solution of hydrochloric acid gas in isopropyl acetate to the solution of the base (27) in toluene followed by filtration. IR (film): nu?=?3483, 1591, 1486?cm-1. 1H NMR (600?MHz, CD3OD): 7.30 (dd, J?=?8.1, 2.2?Hz, 1H), 7.29 (br s, 1H), 7.25 (d, J?=?8.1?Hz, 1H), 4.35 (br s, 2H), 3.50 (t, J?=?6.4?Hz, 2H), 3.10 (br t, J?=?6.4?Hz, 2H). 13C NMR (150?MHz, CD3OD): 133.7, 131.8, 131.5, 131.3, 129.3, 127.7, 45.4, 42.7, 25.6. HRMS calcd. for C9H11ClN+ ([M+H]+): 168.0575, found: 168.0578.

Reference： [1]Tetrahedron,2018,vol. 74,p. 7009 - 7017

63
[ 82771-60-6 ]
[ 552-16-9 ]
2-chloro-5,6-dihydro-8H-isoquinolino[1,2-b]quinazolin-8-one [ No CAS ]

Reference： [1]Organic Letters,2019,vol. 21,p. 1438 - 1443

64
[ 82771-60-6 ]
[ 552-16-9 ]
(7-chloro-3,4-dihydroisoquinolin-2(1H)-yl)(2-nitrophenyl)methanone [ No CAS ]

Reference： [1]Organic Letters,2019,vol. 21,p. 1438 - 1443

65
[ 22245-95-0 ]
[ 82771-60-6 ]

Reference： [1]Organic Letters,2019,vol. 21,p. 1438 - 1443
[2]European Journal of Organic Chemistry,2019,vol. 2019,p. 3649 - 3653
[3]Chemical Communications,2019,vol. 55,p. 12072 - 12075

66
[2-(4-chloro-phenyl)-ethyl]-carbamic acid ethyl ester [ No CAS ]
[ 82771-60-6 ]

Reference： [1]Organic Letters,2019,vol. 21,p. 1438 - 1443
[2]European Journal of Organic Chemistry,2019,vol. 2019,p. 3649 - 3653
[3]Chemical Communications,2019,vol. 55,p. 12072 - 12075

67
[ 82771-60-6 ]
N-(7-chloro-3,4-dihydroisoquinolin-2(1H)-yl)-4-ethylbenzamide [ No CAS ]

Reference： [1]Patent: US2019/100495,2019,A1

68
[ 82771-60-6 ]
7-chloro-2-nitroso-1,2,3,4-tetrahydroisoquinoline [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
62%	With acetic acid; sodium nitrite; In water; at 0℃; for 3.03333h;	General procedure: To ice cold solutions of substituted-1,2,3,4-tetrahydroisoquinolines (1) (1.5 mmol) in a mixture of 2 mL of acetic acid and 2.2 mL of H2O, aqueous solutions of sodium nitrite (NaNO2, 4.5 mmol) in 1.5 mL of H2O were added drop by drop over 2 min at 0 C. in an ice-water bath. The reaction mixtures were stirred for 3 h. (0165) Thin Layer Chromatography (TLC) indicated that the reactions were complete. The reaction mixtures were extracted with CH2Cl2 and the organic layers were washed thrice with brine and dried over sodium sulfate. The solvents were evaporated in vacuo to obtain the crude products. Some products were purified at this stage. For example, 7-Chloro-2-nitroso-1,2,3,4-tetrahdyroisoquinoline was column chromatographed (3:1 Hexane:Ethylacetate, gradient elution) using combiflash column chromatography. The desired compound was obtained in moderate yields (62%). RRN 777-Chloro-2-nitroso-1, 2, 3, 4-tetrahydroisoquinoline (0166) 1HNMR (CDCl3): delta 3.02-3.13 (m, 2H, -CH2), 4.49-4.53 (m, 2H, -CH2), 4.76 (s, 2H, -CH2), 7.13-7.25 (m, 3H, C1?-C4?-H).

Reference： [1]Patent: US2019/100495,2019,A1 .Location in patent: Paragraph 0034; 0164-0166

69
[ 82771-60-6 ]
7-chloro-3,4-dihydroisoquinolin-2(1H)-amine [ No CAS ]

Reference： [1]Patent: US2019/100495,2019,A1

70
[ 82771-60-6 ]
[ 118-92-3 ]
2-chloro-5,6-dihydro-8H-isoquinolino[1,2-b]quinazolin-8-one [ No CAS ]

Reference： [1]European Journal of Organic Chemistry,2019,vol. 2019,p. 3649 - 3653

71
[ 82771-60-6 ]
[ 118-92-3 ]
C₁₆H₁₅ClN₂O [ No CAS ]

Reference： [1]European Journal of Organic Chemistry,2019,vol. 2019,p. 3649 - 3653

72
[ 82771-60-6 ]
[ 114395-17-4 ]
7-chloro-2-(trans-(3-propyloxiran-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2019,vol. 84,p. 7100 - 7112

73
[ 82771-60-6 ]
[ 271-58-9 ]
2-chloro-5,6-dihydro-8H-isoquinolino[1,2-b]quinazolin-8-one [ No CAS ]

Reference： [1]Chemical Communications,2019,vol. 55,p. 12072 - 12075

74
[ 82771-60-6 ]
2-(5-amino-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-7-yl)-2-phenylacetic acid [ No CAS ]
2-(5-amino-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-7-yl)-1-(7-chloro-3,4-dihydroisoquinolin-2(1H)-yl)-2-phenylethan-1-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
28%	With N-ethyl-N,N-diisopropylamine; HATU; In N,N-dimethyl-formamide; at 20℃; for 16h;	To a mixture of 7-chloro-1, 2, 3, 4-tetrahydroisoquinoline (20 mg, 0.12 mmol) , 2- (5-amino-2- (furan-2-yl) -7H-pyrazolo [4, 3-e] [1, 2, 4] triazolo [1, 5-c] pyrimidin-7-yl) -2-phenylacetic acid (40 mg, 0.11 mmol) , DIPEA (100 mg, 0.77 mmol) in DMF (1 mL) was added HATU (50 mg, 0.13 mmol) at rt and the mixture was stirred at rt for 16 hrs. 20 mL of EA was added and the mixture was washed with brine (10 mL x 3) , dried over Na2SO4and concentrated. The resulting residue was purified by prep-TLC (PE/EA = 1: 2) to give the title product (16.0 mg, yield: 28%) .1H NMR (400 MHz, DMSO-d6) delta 8.24 -8.03 (m, 3H) , 7.95 (s, 1H) , 7.50 -7.26 (m, 6H) , 7.24 (s, 1H) , 7.21 -7.03 (m, 2H) , 6.95 -6.88 (m, 1H) , 6.74 (s, 1H) , 4.78 -4.33 (m, 2H) , 3.80 -3.49 (m, 2H) , 2.84 -2.27 (m, 2H) . MS: M/e 525 (M+1)+.

Reference： [1]Patent: WO2020/20097,2020,A1 .Location in patent: Paragraph 0864-0865

75
[ 82771-60-6 ]
[ 100-52-7 ]
C₂₃H₂₀ClNO [ No CAS ]

Reference： [1]Chinese Journal of Chemistry,2020,vol. 38,p. 135 - 138

76
[ 82771-60-6 ]
[ 1858276-04-6 ]
[ 1858282-76-4 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 10 steps 1.1: manganese(IV) oxide / dichloromethane / 16 h / 20 °C 2.1: boron trifluoride diethyl etherate / tetrahydrofuran / 0.33 h / -30 °C 2.2: 0.33 h / -78 °C 3.1: dmap / acetonitrile / 2 h / 20 °C 4.1: Dowex 50WX-2-200 (H) / acetone / 18 h / 20 °C 5.1: n-butyllithium / tetrahydrofuran; hexane / 0.5 h / -78 °C / Inert atmosphere 5.2: 2 h / -78 °C / Inert atmosphere 6.1: manganese(IV) oxide / dichloromethane / 19 h / 20 °C 7.1: potassium carbonate / N,N-dimethyl-formamide / 2 h / 20 °C 8.1: sulphamoyl chloride / N,N-dimethyl-formamide / 3 h / 20 °C 9.1: tetrabutyl ammonium fluoride / tetrahydrofuran / 20 °C 10.1: trifluoroacetic acid / 0.25 h / 20 °C

Reference： [1]Langston, Steven P.; Grossman, Stephen; England, Dylan; Afroze, Roushan; Bence, Neil; Bowman, Douglas; Bump, Nancy; Chau, Ryan; Chuang, Bei-Ching; Claiborne, Christopher; Cohen, Larry; Connolly, Kelly; Duffey, Matthew; Durvasula, Nitya; Freeze, Scott; Gallery, Melissa; Galvin, Katherine; Gaulin, Jeffrey; Gershman, Rachel; Greenspan, Paul; Grieves, Jessica; Guo, Jianping; Gulavita, Nanda; Hailu, Shumet; He, Xingyue; Hoar, Kara; Hu, Yongbo; Hu, Zhigen; Ito, Mitsuhiro; Kim, Mi-Sook; Lane, Scott Weston; Lok, David; Lublinsky, Anya; Mallender, William; McIntyre, Charles; Minissale, James; Mizutani, Hirotake; Mizutani, Miho; Molchinova, Nina; Ono, Koji; Patil, Ashok; Qian, Mark; Riceberg, Jessica; Shindi, Vaishali; Sintchak, Michael D.; Song, Keli; Soucy, Teresa; Wang, Yana; Xu, He; Yang, Xiaofeng; Zawadzka, Agatha; Zhang, Ji; Pulukuri, Sai M. [Journal of Medicinal Chemistry, 2021, vol. 64, # 5, p. 2501 - 2520]

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 82771-60-6 ]

Chlorides

[ 73075-49-7 ]

6,7-Dichloro-1,2,3,4-tetrahydroisoquinoline hydrochloride

Similarity: 0.95

[ 90389-47-2 ]

N-(3-Chlorobenzyl)ethanamine hydrochloride

Similarity: 0.90

[ 39180-82-0 ]

N-(3-Chlorobenzyl)ethanamine

Similarity: 0.90

[ 61563-33-5 ]

8-Chloro-1,2,3,4-tetrahydroisoquinoline hydrochloride

Similarity: 0.89

[ 75416-50-1 ]

8-Chloro-1,2,3,4-tetrahydroisoquinoline

Similarity: 0.89

Related Parent Nucleus of
[ 82771-60-6 ]

Quinolines

[ 2585-04-8 ]

6-Chloro-4-methylquinolin-2(1H)-one

Similarity: 0.55

[ 612-57-7 ]

6-Chloroquinoline

Similarity: 0.53

[ 73108-76-6 ]

7-Chloro-8-methylquinolin-2(1H)-one

Similarity: 0.53

[ 635-27-8 ]

5-Chloroquinoline

Similarity: 0.52

[ 19655-46-0 ]

8-Chloro-6-methylquinoline

Similarity: 0.52

Tetrahydroquinolines

[ 49716-18-9 ]

6-Chloro-1,2,3,4-tetrahydroquinoline

Similarity: 0.73

[ 90562-33-7 ]

5-Chloro-1,2,3,4-tetrahydroquinoline hydrochloride

Similarity: 0.72

[ 90562-34-8 ]

7-Chloro-1,2,3,4-tetrahydroquinoline hydrochloride

Similarity: 0.70

[ 90562-35-9 ]

7-Chloro-1,2,3,4-tetrahydroquinoline

Similarity: 0.70

[ 1783400-57-6 ]

6,7-Dichloro-1,2,3,4-tetrahydroquinoline

Similarity: 0.69

Tetrahydroisoquinolines

[ 73075-49-7 ]

6,7-Dichloro-1,2,3,4-tetrahydroisoquinoline hydrochloride

Similarity: 0.95

[ 61563-33-5 ]

8-Chloro-1,2,3,4-tetrahydroisoquinoline hydrochloride

Similarity: 0.89

[ 75416-50-1 ]

8-Chloro-1,2,3,4-tetrahydroisoquinoline

Similarity: 0.89

[ 22246-02-2 ]

6-Chloro-3,4-dihydroisoquinolin-1(2H)-one

Similarity: 0.75

[ 91-21-4 ]

1,2,3,4-Tetrahydroisoquinoline

Similarity: 0.73

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 82771-60-6 ] {[proInfo.proName]}

Quality Control of [ 82771-60-6 ]

Related Doc. of [ 82771-60-6 ]

Product Details of [ 82771-60-6 ]

Calculated chemistry of [ 82771-60-6 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 82771-60-6 ]

Application In Synthesis of [ 82771-60-6 ]

[ 82771-60-6 ] Synthesis Path-Upstream 1~16

[ 82771-60-6 ] Synthesis Path-Downstream 1~76

Related Functional Groups of [ 82771-60-6 ]

Chlorides

Related Parent Nucleus of [ 82771-60-6 ]

Quinolines

Tetrahydroquinolines

Tetrahydroisoquinolines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 82771-60-6 ]

Related Parent Nucleus of
[ 82771-60-6 ]